Clinical Trial Update: A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS) [Phase 3]

View source ↗

Summary

This Phase 3 trial assessed golimumab in children with juvenile idiopathic arthritis who had poor response to methotrexate; the study was terminated and results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis

Drugs mentioned

• Golimumab (golimumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Juvenile Idiopathic Arthritis | Phase 3 | Status: TERMINATED | Results posted: 2014-09-29